NLS Pharmaceutics AG

NASDAQ: NLSP · Real-Time Price · USD
2.54
-0.07 (-2.68%)
At close: Aug 15, 2025, 3:59 PM
2.58
1.58%
After-hours: Aug 15, 2025, 07:55 PM EDT

NLS Pharmaceutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2024 Q4 2023 Q2 2023 Q4 2022 Q2 2022 Q4 2021 Q2 2021
Period Ending Jun 30, 2024 Dec 31, 2023 Jun 30, 2023 Dec 31, 2022 Jun 30, 2022 Dec 31, 2021 Jun 30, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
11.41K 11.41K 11.41K 11.41K 10.73K 10.05K 5.02K
Gross Profit
-11.41K -11.41K -11.41K -11.41K -10.73K -10.05K -5.02K
Operating Income
-2.06M -7.55M -14.34M -15.48M -16.01M -11.86M -5.76M
Interest Income
n/a 0.13 91.82 100.87 9.18 68.13 213.50
Pretax Income
-2.04M -7.62M -15.47M -16.5M -15.98M -11.95M -6.23M
Net Income
-2.04M -7.62M -15.47M -16.5M -15.98M -11.95M -6.23M
Selling & General & Admin
1.78M 3.16M 6.52M 6.49M 6.39M 5.93M 3.89M
Research & Development
272.87K 4.39M 7.82M 8.98M 9.6M 5.92M 1.86M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
2.05M 7.55M 14.33M 15.47M 16M 11.85M 5.76M
Interest Expense
145.02K 145.15K 91.81K 100.87K 9.18K 68.13K 213.5K
Selling & Marketing Expenses
1.77M 3.16M 6.51M 6.49M 6.39M 5.93M 3.89M
Cost & Expenses
2.06M 7.55M 14.34M 15.48M 16.01M 11.86M 5.76M
Income Tax Expense
-4 -8 -8 -8 -3.5 -1.5 -1.5
Shares Outstanding (Basic)
41.95M 32.43M 38.18M 26.68M 15.89M 14.75M 11.07M
Shares Outstanding (Diluted)
41.95M 32.43M 38.18M 26.68M 15.89M 14.75M 11.07M
EPS (Basic)
-0.14 -0.34 -0.49 -0.83 -1.04 -0.92 -0.76
EPS (Diluted)
-0.14 -0.34 -0.49 -0.83 -1.04 -0.92 -0.76
EBITDA
-6.35M -11.95M -14.33M -15.47M -16.02M -11.88M -6.02M
EBIT
-6.36M -11.96M -14.34M -15.48M -16.01M -11.86M -6.03M
Depreciation & Amortization
5.71K 5.71K 11.41K 11.41K 10.73K 10.05K 6.24K